CIRCLE8 GROUP INC 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File No. 333-150332 SEQLL INC. (Exact name of registrant as specified in its charter) Delaware 46-5319744 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3 Federal Street Billerica , MA 01821 (Address of principal executive office) (Zip Code) (781) 460-6016 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.0001 per share SQL The Nasdaq Stock Market LLC Warrants to purchase Common Stock SQLLW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of November 8, 2022, there were 11,886,379 shares of registrant’s common stock outstanding. TABLE OF CONTENTS PAGE PART I FINANCIAL INFORMATION 1 Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 1 Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2022 and 2021. 2 Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021. 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021. 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosures about Market Risk 23 Item 4. Controls and Procedures 23 PART II OTHER INFORMATION 24 Item 1. Legal Proceedings 24 Item 1A. Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Default Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25 Signatures 26 i EXPLANATORY NOTE In this Quarterly Report on Form 10-Q, and unless the context otherwise requires, the “Company,” “we,” “us,” and “our” refer to SeqLL Inc. and its wholly owned subsidiary SeqLL, LLC, taken as a whole. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in this report and in other documents which we file with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to: ● the success, cost and timing of our product development activities, including statements regarding the timing of initiation and completion of our research and development programs; ● developments regarding next generation sequencing technologies; ● our expectations regarding the market size and growth potential for our business; ● our ability to generate sustained revenue or achieve profitability; ● the potential for our identified research priorities to advance our technology; ● the pricing and expected gross margin for our products; ● the other factors discussed in the “Risk Factors” section and elsewhere in this report. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the filing date of this report. ii PART I. FINANCIAL INFORMATION Item 1: Financial Statements SeqLL Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2022 2021 Assets (Unaudited) Current assets Cash and cash equivalents $ 4,453,521 $ 4,015,128 Marketable securities 2,499,685 5,933,364 Accounts receivable, net of allowance for doubtful accounts of $ 6,016 29,514 30,714 Other receivables 60,000 34,965 Inventory 246,904 224,155 Prepaid expenses 222,831 186,056 Total current assets 7,512,455 10,424,382 Other assets Property and equipment, net 548,966 265,267 Operating lease right-of-use asset 1,161,743 - Other assets 127,759 50,488 Total assets $ 9,350,923 $ 10,740,137 Liabilities and Stockholders’ Equity Current liabilities Accounts payable $ 583,573 $ 871,364 Accrued expenses 304,101 311,405 Non-convertible promissory notes - current - 1,375,000 Current portion of operating lease liability 83,145 - Total current liabilities 970,819 2,557,769 Non-current liabilities Operating lease liability, less current portion 1,491,649 - Non-convertible promissory notes - long-term 1,375,000 - Total liabilities 3,837,468 2,557,769 Commitments and contingencies (Note 11) Stockholders’ equity Preferred stock, $ 0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding - - Common stock, $ 0.00001 par value; 80,000,000 shares authorized; 11,886,379 shares issued and outstanding 119 119 Additional paid-in capital 22,786,005 22,596,100 Accumulated deficit ( 17,272,669 ) ( 14,413,851 ) Total stockholders’ equity 5,513,455 8,182,368 Total liabilities and stockholders’ equity $ 9,350,923 $ 10,740,137 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 SeqLL Inc. Condensed Consolidated Statements of Operations (Unaudited) Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Revenue Sales $ - $ 15,937 $ 1,177 $ 48,021 Grant revenue - 34,964 77,482 127,009 Total revenue - 50,901 78,659 175,030 Cost of sales - 4,049 690 44,792 Gross profit - 46,852 77,969 130,238 Operating expenses Research and development 428,771 90,658 1,129,286 133,074 General and administrative 489,729 360,944 1,700,340 1,173,565 Total operating expenses 918,500 451,602 2,829,626 1,306,639 Operating loss ( 918,500 ) ( 404,750 ) ( 2,751,657 ) ( 1,176,401 ) Other (income) and expenses Unrealized loss (gain) on marketable securities 242 - ( 54,266 ) - Realized loss on marketable securities - - 106,324 - Interest and other income ( 9,981 ) ( 93 ) ( 18,457 ) ( 190,193 ) Change in fair value of convertible notes - 193,776 - 195,962 Loss on extinguishment of convertible notes - - - 934,257 Interest expense 17,188 41,066 73,560 189,993 Net loss $ ( 925,949 ) $ ( 639,499 ) $ ( 2,858,818 ) $ ( 2,306,420 ) Net loss per share - basic and diluted $ ( 0.08 ) $ ( 0.09 ) $ ( 0.24 ) $ ( 0.41 ) Weighted average common shares - basic and diluted 11,886,379 7,171,232 11,886,379 5,642,100 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 SeqLL Inc. Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) Preferred Stock Common Stock Additional Paid-In Accumulated Total Stockholders’ Shares Amount Shares Amount Capital Deficit Equity Balance as of December 31, 2021 - $ - 11,886,379 $ 119 $ 22,596,100 $ ( 14,413,851 ) $ 8,182,368 Stock-based compensation expense - - - - 55,914 - 55,914 Net loss - - - - - ( 937,954 ) ( 937,954 ) Balance as of March 31, 2022 - - 11,886,379 119 22,652,014 ( 15,351,805 ) 7,300,328 Stock-based compensation expense - - - - 66,995 - 66,995 Net loss - - - - - ( 994,915 ) ( 994,915 ) Balance as of June 30, 2022 - - 11,886,379 119 22,719,009 ( 16,346,720 ) 6,372,408 Stock-based compensation expense - - - - 66,996 - 66,996 Net loss - - - - - ( 925,949 ) ( 925,949 ) Balance as of September 30, 2022 - $ - 11,886,379 $ 119 $ 22,786,005 $ ( 17,272,669 ) $ 5,513,455 Preferred Stock Common Stock Additional Paid-In Accumulated Total Stockholders’ Shares Amount Shares Amount Capital Deficit Equity (Deficit) Balance as of December 31, 2020 5,791,665 $ 58 4,864,862 $ 49 $ 6,856,020 $ ( 10,710,293 ) ( 3,854,166 ) Stock-based compensation expense - - - - 1,007 - 1,007 Net loss - - - - - ( 1,414,618 ) ( 1,414,618 ) Balance as of March 31, 2021 5,791,665 58 4,864,862 49 6,857,027 ( 12,124,911 ) ( 5,267,777 ) Stock-based compensation expense - - - - 3,192 - 3,192 Net loss - - - - - ( 252,303 ) ( 252,303 ) Balance as of June 30, 2021 5,791,665 58 4,864,862 49 6,860,219 ( 12,377,214 ) ( 5,516,888 ) Stock-based compensation expense - - - - 214,745 - 214,745 Conversion of preferred stock into common stock ( 5,791,665 ) ( 58 ) 3,130,622 31 27 - - Conversion of convertible notes into common stock - - 641,895 6 3,222,300 - 3,222,306 Issuance of Units and warrants to underwriters in initial public offering, net of issuance costs of $ 1,555,976 - - 3,060,000 31 11,453,614 - 11,453,645 Issuance of common stock to underwriters in initial public offering, net of issuance costs of $ 71,199 - - 189,000 2 730,161 - 730,163 Net loss - - - - - ( 639,499 ) ( 639,499 ) Balance as of September 30, 2021 - $ - 11,886,379 $ 119 $ 22,481,066 $ ( 13,016,713 ) $ 9,464,472 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 SeqLL Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Nine months ended September 30, 2022 2021 Cash Flows from Operating Activities Net loss $ ( 2,858,818 ) $ ( 2,306,420 ) Adjustment to reconcile net loss to net cash used in operating activities: Depreciation 58,718 64,543 Unrealized gain on marketable securities ( 54,266 ) - Realized loss on marketable securities 106,324 - Loss on extinguishment of notes - 934,257 Stock-based compensation 189,905 218,944 Change in fair value of convertible notes - 195,962 Non-cash lease expense 100,291 - Changes in operating assets and liabilities: Accounts receivable, net 1,200 ( 25 ) Other receivables ( 25,035 ) 73,851 Prepaid expenses ( 36,775 ) ( 270,150 ) Inventory ( 22,749 ) ( 5,704 ) Other assets ( 77,271 ) - Accounts payable ( 287,791 ) ( 94,674 ) Accrued expenses ( 7,304 ) 166,445 Net cash used in operating activities ( 2,913,571 ) ( 1,022,971 ) Cash Flows from Investing Activities Purchases of lab equipment ( 29,657 ) ( 5,250 ) Purchases of marketable securities ( 2,500,517 ) - Sales of marketable securities 5,882,138 - Net cash provided by (used in) investing activities 3,351,964 ( 5,250 ) Cash Flows from Financing Activities Proceeds from issuance of units, gross - 13,009,621 Proceeds from issuance of common stock to underwriters, gross - 801,362 Payment for issuance costs of units and common stock - ( 1,558,193 ) Proceeds from issuance of convertible notes - 250,000 Settlement of convertible notes - ( 141,884 ) Proceeds from loan payable – related party - 140,000 Payment of loan payable – related party - ( 166,000 ) Net cash provided by financing activities - 12,334,906 Net increase in cash and cash equivalents 438,393 11,306,685 Cash and cash equivalents, beginning of period 4,015,128 - Cash and cash equivalents, end of period $ 4,453,521 $ 11,306,685 Non-cash investing activities Right-of-use asset acquired through operating lease $ 1,257,495 $ - Leasehold improvements financed through tenant improvement allowance $ 312,760 $ - Conversion of notes at initial public offering into common stock $ - $ 3,222,206 Issuance costs in accounts payable $ - $ 68,982 Fair value of warrants for common stock issued to underwriters $ - $ 1,647,076 Conversion of preferred stock par value to common stock and additional paid-in capital $ - $ 58 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 SeqLL Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) Note 1 – Nature of Operations and Basis of Presentation SeqLL Inc. was incorporated as a Delaware corporation on April 3, 2014. On April 8, 2014, SeqLL Inc. acquired a 100 % ownership interest in SeqLL, LLC (“Subsidiary”), a domestic limited liability company formed on March 11, 2013 in the State of Massachusetts. SeqLL Inc. is a holding company of the Subsidiary (together the “Company” or “SeqLL”) and is a life sciences company focused on the development and application of innovative genetic analysis technologies and the monetization of that technology and related intellectual property. The Subsidiary owns technology to enable the analysis of large volumes of genetic material by directly sequencing single molecules of DNA or RNA. The Subsidiary’s principal office is located in Billerica, Massachusetts. Initial Public Offering On August 31, 2021, the Company completed its initial public offering (“IPO”) whereby it sold 3,060,000 units, each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of common stock at an exercise price of $ 4.25 per share (the “Warrants”), at a price to the public of $ 4.25 per unit. The gross proceeds from the IPO were approximately $ 13 million and were offset by $ 3.2 million in offering costs, of which $ 1.6 million was paid in cash and $ 1.6 million was issued in warrants to Maxim Group LLC (“Underwriter”) (see Note 8). In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into 3,130,622 shares of common stock (see Note 9). Additionally, the outstanding convertible notes converted into 641,895 shares of common stock (see Note 7). Pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option to purchase up to 459,000 additional shares of common stock, and/or 459,000 additional Warrants, to cover over-allotments in connection with the Offering. The Underwriter partially exercised this option and purchased 459,000 Warrants on August 31, 2021, at $ 0.01 per Warrant. On September 29, 2021, the Company issued 189,000 shares of common stock to the underwriters at a price of $ 4.24 per share from the exercise of the overallotment option, raising the net proceeds of approximately $ 730,000 , net of offering costs. Notice from the Nasdaq Stock Market On June 21, 2022, SeqLL received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for its common stock has fallen below $ 1.00 per share for 30 consecutive business days, the Company no longer complies with the $ 1.00 minimum bid price requirement for continued listing. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock or its warrants to purchase common stock under the symbols “SQL” and “SQLLW,” respectively. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by December 18, 2022, the Company may be eligible for an additional grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period. If the Company meets these requirements, the Nasdaq staff will grant an additional 180 calendar days for the Company to regain compliance with the minimum bid price requirement. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process. 5 Risks and Uncertainties The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel. Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control. The Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company’s business. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, SeqLL, LLC. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2022 and its results of operations for the three- and nine-months ended September 30, 2022 and 2021, and changes in shareholders’ equity and cash flows for the periods presented. The results disclosed in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 filed with the Securities and Exchange Commission. Note 2 – Significant Accounting Policies During the nine-month period ended September 30, 2022, there were no changes to the significant accounting policies in relation to what was described in the Annual Report on Form 10-K for the year ended December 31, 2021, other than the items noted in the Recently Adopted Accounting Standards section below. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include but are not limited to stock-based compensation expense and research and development accruals. Actual results could differ from those estimates and changes in estimates may occur. Investments in marketable securities The Company accounts for its investments in debt securities in accordance with Accounting Standards Codification (“ASC”) 320, Investments — Debt Securities (“ASC 320”). Debt securities, which are comprised of investments in U.S. Treasury Securities, are measured at fair value, based on quoted market prices. As the Company has classified its investments in debt securities as available-for-sale, the Company recognizes all unrealized gains and losses in other comprehensive income, net of tax, and recognizes all realized gains and losses in the Company’s statement of operations. The Company accounts for its investments in equity securities in accordance with ASC 321, Investments — Equity Securities (“ASC 321”). Equity securities, which are comprised of investments in mutual funds shares, are measured at fair value, based on quoted market prices, with all gains and losses reported in the Company’s statement of operations. 6 The Company may sell its debt or equity securities in response to changes in interest rates, risk/reward characteristics, liquidity needs or other factors. Inventory Inventory consists of finished goods, work-in-process and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method. As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory. The Company evaluates the carrying cost of finished goods, work-in-process and raw materials items. To the extent that such costs exceed future demand estimates and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable inventories. Inventory consisted of the following: September 30, December 31, 2022 2021 Raw materials $ 118,216 $ 91,995 Work in process 128,688 132,160 Total inventory $ 246,904 $ 224,155 Stock-based Compensation The Company’s share-based compensation program grant awards include stock options and restricted stock awards to employees, directors and consultants. The fair value of stock option grants is estimated as of the date of the grant using the Black-Scholes option pricing model. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. The fair value of the stock-based awards is then expensed over the requisite service period, generally the vesting period, for each award. The Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. No dividend yield was assumed as the Company does not pay dividends on its common stock. The Company recognizes forfeitures related to stock-based awards as they occur. The Company has periodically granted stock options and restricted stock awards to consultants for services, pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled. For awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally the period services are rendered by such consultants and non-employees. The assumptions used in determining the fair value of share-based awards granted during the nine-months ended September 30, 2022 are as follows: September 30, 2022 Risk-free interest rate 1.64 % Expected option life 6 – 6.1 years Expected dividend yield 0 % Expected stock price volatility 54 % 7 Segments The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Leases In the first quarter of 2022, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) . The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company recognizes right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases. The Company accounts for the leases of less than 12 months as short-term leases. See the Recently Adopted Accounting Standards below for additional information related to the adoption of this accounting standard. Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive: September 30, 2022 2021 Stock options 2,003,919 818,915 Warrants for common stock 4,388,185 4,393,396 Recently Adopted Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022, which had no material impact to the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”) which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to the Company’s condensed consolidated financial statements. 8 Recently Issued Accounting Standards The Company does not believe that other recently issued but not yet effective accounting pronouncements are expected to have a material effect on the Company’s condensed consolidated financial statements. Note 3 – Accrued Expenses Accrued expenses consisted of the following: September 30, December 31, 2022 2021 Accrued interest $ 289,633 $ 216,073 Other 14,468 95,332 $ 304,101 $ 311,405 Note 4 – Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. As of September 30, 2022, the Company had $ 4,002,061 of investments in U.S. Treasury Securities, of which $ 1,502,376 was included in cash and cash equivalents. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices. As of December 31, 2021, the Company had $ 5,993,385 of investments in mutual funds, of which $ 60,021 was included in cash and cash equivalents. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices. There were no liabilities measured at fair value at September 30, 2022 or December 31, 2021. 9 The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis for the nine-month period ended September 30, 2021. Convertible Notes Balance at December 31, 2020 $ - Issuance of Amended Notes 3,168,236 Change in fair value of convertible notes 195,962 Fair value of convertible notes at IPO date ( 3,364,198 ) Balance at September 30, 2021 $ - At the IPO date, the Amended Notes (as defined in Note 7) were converted into 641,895 shares of common stock (see Note 7). The interest expense of $ 89,239 for the period between the date of the Conversion Agreements related to the Amended Notes (see Note 7) and September 30, 2021 was included in the change in fair value of the Amended Notes. There were no assets or liabilities measured at fair value on a non-recurring basis during the three- and nine- months ended September 30, 2022 or 2021. The carrying values of financial instruments such as accounts receivable, net, other receivables, accounts payable, and accrued expenses approximated fair value as of September 30, 2022 and December 31, 2021 due to their short-term maturities. The carrying value of the Company’s Non-Convertible Promissory Note approximated its fair value as of September 30, 2022 and December 31, 2021. Note 5 – Stock Option Plan The Company’s 2014 Equity Incentive Plan (the “2014 Plan”) permits the grant of options for its common stock and shares of common stock to its employees, board members and consultants for up to 3,500,000 shares. As of September 30, 2022, there were 1,496,081 shares available for future issuance under the 2014 Plan. Generally, option awards are granted with an exercise price equal to the fair value of the Company’s stock at the date of grant and vest over a period of three to four years . No option may have a term in excess of ten years from the option grant date. Certain option and share awards provide for accelerated vesting if there is a change in control (as defined by the 2014 Plan). The weighted average grant date fair value of options granted in the nine-month period ended September 30, 2022 was $ 0.89 per share. No option awards were granted during the nine months ended September 30, 2021. The stock option activity for the period ended September 30, 2022 is as follows: Number of Options Weighted- Average Exercise Price per Share Weighted Average Remaining Contractual Term (in Years) Outstanding as of December 31, 2021 918,919 $ 2.09 5.79 Granted 1,085,000 $ 1.71 Outstanding of September 30, 2022 2,003,919 $ 1.88 7.34 Exercisable at September 30, 2022 919,088 $ 2.09 5.04 10 During the three months ended September 30, 2022 and 2021, the Company recorded $ 66,996 and $ 214,745 , respectively, of stock-based compensation associated with vesting of stock options, of which $ 46,394 and $ 214,745 were included in general and administrative expenses for the three months ended September 30, 2022 and 2021, respectively, and $ 20,602 and $ 0 were included in research and development expenses for the three months ended September 30, 2022 and 2021, respectively. During the nine months ended September 30, 2022 and 2021, the Company recorded $ 189,905 and $ 218,944 , respectively, of stock-based compensation associated with vesting of stock options, of which $ 131,533 and $ 218,944 were included in general and administrative expenses for the nine months ended September 30, 2022 and 2021, respectively, and $ 58,372 and $ 0 were included in research and development expenses for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, there was approximately $ 777,808 of unrecognized compensation expense related to unvested share-based compensation awards, which will be recognized over a weighted average period of approximately 1.62 years. Note 6 – Related Party Transactions At September 30, 2022 and December 31, 2021, the Company had the following outstanding payables to its shareholders for past services, which are included within the Company’s accounts payable above: September 30, 2022 December 31, 2021 Genomic Diagnostic Technologies $ - $ 23,725 St. Laurent Institute 232,418 313,679 St. Laurent Realty, Inc. 7,558 27,913 Total related party payables $ 239,976 $ 365,317 The above entities are affiliated with (1) William C. St. Laurent, a former member of the Company’s board of directors, (2) relatives of Mr. St. Laurent or (3) entities controlled by the St. Laurent family, who are controlling shareholders of the Company. St. Laurent Realty, Inc. and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support; St. Laurent Institute, a non-for-profit company, provided bioinformatics specialist support for certain sequencing services. Note 7 – Notes Payable The Company entered into a series of convertible promissory notes (the “Convertible Notes”) through April 8, 2019, with certain preferred stockholders amounting to $ 905,000 . The Convertible Notes had a one-year term and accrued interest at 10 % per annum. The Convertible Notes were convertible at the lower of $ 3.10 per share or a 20 % discount to the share price paid by the purchasers of equity securities in the Company’s next Qualified Financing, as defined in the convertible note agreement. From April 29, 2019, to April 29, 2020, the Company entered into a series of non-convertible promissory notes (the “Promissory Notes”) with a certain preferred stockholder amounting to $ 1,375,000 . The Promissory Notes had a one-year term with interest accruing at 10 % per annum. In November and December 2020, the Company issued senior secured convertible promissory notes to a third-party investor amounting to $ 200,000 . These notes accrued interest at 10 % per annum, were to be repaid at the earlier of December 31, 2022 , or the Company’s next qualified financing of a minimum of $ 7.5 million (as defined in the notes agreement) and were convertible at $ 3.75 per share. 11 On December 31, 2020, the Company issued a non-convertible promissory note to St. Laurent Investments LLC amounting to $ 426,020 due July 31, 2022 , bearing 10 % interest per annum in exchange for the accrued interest on all its notes of the Company outstanding through that date. From January to March 2021, the Company issued senior secured convertible promissory notes to investors for total proceeds of $ 250,000 . The Convertible Notes accrued interest at 10 % per annum, matured at the earlier of December 31, 2022 , or the Company’s next qualified equity offering of a minimum of $ 7.5 million, and were convertible at $ 3.75 per share. On February 3, 2021, the preferred stockholder and the holder of $ 2,910,710 in the Convertible Notes and Promissory Notes of the Company granted the Company an extension on all its notes of the Company to be repaid on or before July 31, 2022. This amendment was accounted for on a prospective basis under the troubled debt restructuring guidance. In March 2021, the Company entered into a series of agreements with the noteholders to automatically convert $ 786,730 in outstanding Promissory Notes and $ 1,305,000 in Convertible Notes (together, “Amended Notes”), to common stock upon the closing of the IPO (“Conversion Agreements”), of which $ 1,552,683 was held by St. Laurent Investments, LLC and its affiliates. Under the terms of the conversion agreements, $ 826,020 and $ 1,265,710 in Amended Notes were to be converted at the closing of the IPO based on the $ 3.75 and $ 3.10 conversion prices, respectively. Since the automatic conversion could result in a material benefit to the noteholders, this amendment was deemed substantive and was accounted for as an extinguishment of debt. Accordingly, the Company recognized a loss on extinguishment of debt totaling $ 934,257 in the consolidated statement of operations for the three months ended March 2021, which represented the excess of the fair value of the Amended Notes totaling $ 3,118,235 over their carrying value of $ 2,183,978 . The Company elected the option to account for the Amended Notes at fair value, with the changes in fair value recognized in the statement of operations. The fair value of the Amended Notes was estimated using probability weighted expected payouts under various settlement scenarios, discounted to their present value based on the estimated effective rate of return. On April 29, 2021, the Company entered into an agreement with a noteholder to automatically convert an additional $ 50,000 in outstanding Amended Notes, including any accrued interest, to common stock upon the closing of the IPO at the conversion price of $ 3.75 per share. At the IPO date, the Amended Notes automatically converted based on their original terms into 641,895 shares of common stock. The fair value of the Amended Notes of $ 3,364,198 immediately prior to the conversion, less a $ 141,884 cash payment related to the accrued interest, was reclassified into the additional paid in capital on the condensed consolidated balance sheet. The fair value of the Amended Notes at the conversion date was estimated based on the fair value of the common stock issued upon the conversion. The Company recognized $ 195,962 loss due to the change in fair value of the Amended Notes between the amendment date and their conversion at the IPO date. In October 2021, the Company entered into an agreement with St. Laurent Investments LLC to reduce the interest on $ 1,375,000 principal amount of the Promissory Notes from 10 % to 5 % per year starting on October 1, 2021. The Company accounted for this transaction as a modification on a prospective basis. In October 2021, the Company repaid $ 270,000 of the Promissory Notes to William C. St Laurent in cash. In connection with all the Convertible Notes and Promissory Notes issued during 2021 and 2020, the Company issued warrants to noteholders to purchase the total of 66,665 and 53,333 shares of the Company’s common stock, including 11,466 to the placement agent (see Note 8). The fair values of these warrants were immaterial at issuance. In June 2022, the Company entered into an agreement with St. Laurent Investments LLC to extend the maturity date of the $ 1,375,000 Promissory Note to July 31, 2024 . The Company accounted for this transaction as a modification on a prospective basis. For the three months ended September 30, 2022 and 2021, interest expense was $ 17,188 and $ 41,066 , respectively. For the nine months ended September 30, 2022 and 2021, interest expense was $ 73,560 and $ 189,993 , respectively. 12 Note 8 – Common Stock Warrants The following table summarizes information with regard to outstanding warrants to purchase the Company’s common stock as of September 30, 2022: Issuance Date Number of Shares Issuable Upon Exercise of Outstanding Warrants Exercise Price Expiration Date 8/30/2018 3,088 $ 3.10 8/29/2023 9/30/2018 60,506 $ 3.10 9/29/2023 9/30/2018 486,486 $ 2.16 9/29/2023 10/17/2018 1,157 $ 3.10 10/16/2023 11/2/2018 964 $ 3.10 11/1/2023 11/9/2018 964 $ 3.10 11/8/2023 11/16/2018 964 $ 3.10 11/15/2023 11/29/2018 964 $ 3.10 11/28/2023 12/21/2018 964 $ 3.10 12/20/2023 12/27/2018 964 $ 3.10 12/26/2023 1/31/2019 1,930 $ 3.10 1/30/2024 2/7/2019 1,640 $ 3.10 2/6/2024 2/21/2019 1,640 $ 3.10 2/20/2024 3/20/2019 3,378 $ 3.10 3/18/2024 4/8/2019 1,930 $ 3.10 4/6/2024 11/19/2020 53,333 $ 4.10 6/30/2024 11/19/2020 8,533 $ 4.10 6/30/2024 1/8/2021 13,333 $ 4.10 6/30/2024 1/11/2021 26,666 $ 4.10 6/30/2024 2/13/2021 13,333 $ 4.10 6/30/2024 3/16/2021 10,665 $ 4.10 6/30/2024 3/16/2021 13,333 $ 4.10 6/30/2024 8/31/2021 3,519,000 $ 4.25 8/31/2026 8/31/2021 153,000 $ 4.675 8/26/2026 9/29/2021 9,450 $ 4.675 8/26/2026 4,388,185 During the nine-month period ended September 30, 2022, warrants to purchase 5,211 shares of common stock with an exercise price of $ 3.10 expired. 13 Note 9 – Preferred Stock The Company had outstanding preferred stock as of December 31, 2020: Shares authorized Shares issued Issuance price per share Series A-1 Convertible Preferred Stock 3,125,000 $ 0.32 Series A-2 Convertible Preferred Stock 2,666,665 $ 1.68 Series A Preferred stock 20,000,000 5,791,665 The Series A-1 Preferred Stock (“Series A-1”) and Series A-2 Preferred Stock (“Series A-2”) collectively the Preferred Stock”, could be converted at any time at the election of the holder into common stock at an initial conversion price determined by dividing the Series A-1 original issue price of $ 0.59 , as amended, by the Series A-1 conversion price of $ 0.59 ; and the Series A-2 original issue price of $ 3.10 , as amended, by the Series A-2 conversion price of $ 3.10 ; both were subject to adjustment for stock splits, stock combinations and the like, and to a weighted-average adjustment for future issuances of common stock, warrants or rights to purchase common stock or securities convertible into common stock for a consideration per share that is less than the then-applicable conversion price, subject to certain exceptions listed in the Charter. The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class. In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock, upon the consent of the holders of a majority of the Preferred Stock, automatically converted into 3,130,622 shares of common stock. Note 10 – Marketable Securities In January 2022, the Company sold all of its marketable securities in its possession at December 31, 2021 with the original cost $ 5,988,462 . The Company realized $ 106,324 loss on the sale of these securities and recorded the unrealized gain of $ 54,508 on its investments in marketable securities for the nine months ended September 30, 2022. In September 2022, the Company purchased marketable securities at a cost of $ 2,499,928 . The unrealized loss was immaterial for the three and nine months ended September 30, 2022. Note 11 – Commitments and Contingencies The Company’s office space lease in Woburn, Massachusetts (the “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November 2020 and was terminated in February 2022. The rent expense for this lease was $ 0 and $ 52,004 for the three months ended September 30, 2022 and 2021, respectively, and $ 14,239 and $ 143,970 for the nine months ended September 30, 2022 and 2021, respectively. On February 2, 2022, the Company entered into a lease agreement for approximately 15,638 square feet of its new corporate office space in Billerica, Massachusetts (the “Billerica Lease”). The Billerica Lease has a term of 92 months from its effective date and included access to certain additional office space until August 1, 2022. In addition, the Company is required to share in certain taxes and operating expenses of the Billerica Lease. 14 The Billerica Lease is classified as an operating lease. At the inception date of the Billerica Lease, the Company recorded a right-of-use asset of $ 1,481,646 in operating lease right-of-use asset, as well as a lease liability of $ 12,222 in current liabilities and $ 1,547,614 in long-term liabilities. The operating lease right-of use asset is less than that of the Company’s lease liabilities as of the lease inception date. This is due to the fact that the Company as part of the Billerica Lease was allowed certain tenant improvement allowances, which amounted to $ 78,190 at lease inception. This lease liability represented the net present value of future lease payments for the lease utilizing a discount rate of 5.98 %, which corresponded to the Company’s incremental borrowing rate. In August 2022, the Company received the tenant improvement allowance from the landlord, which totalled approximately $ 312,760 . This allowance covered the leasehold improvements to the Billerica space and was accounted for as a reduction to the right-of-use asset. As of September 30, 2022, the remaining lease term was 7.1 years. The Company recorded expense related to the Billerica Lease in the amount of $ 41,893 and $ 145,709 for the three-and nine-months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2022, the Company made cash payments of $ 7,850 and $ 45,418 , respectively, for amounts included in the measurement of lease liabilities. The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of September 30, 2022: 2022 (remaining) $ 42,949 2023 197,307 2024 275,875 2025 284,151 Thereafter 1,142,709 Total undiscounted lease liabilities $ 1,942,991 Less effects of discounting ( 368,197 ) Total lease liabilities $ 1,574,794 Reported as of September 30, 2022: Current portion of operating lease liability $ 83,145 Operating lease liability, less current portion 1,491,649 Total lease liabilities $ 1,574,794 Note 12 — Paycheck Protection Program On May 5, 2021, the Company applied for and received a loan for $ 190,100 in connection with the Paycheck Protection Program (“PPP”) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (“CARES”) Act that was signed into law on March 27, 2020. The loan had a term of 5 years, was unsecured and was guaranteed by the Small Business Administration (“SBA”). The loan bore interest at one percent per annum. Loan payments were to be deferred for borrowers who apply for loan forgiveness until the SBA remits the borrower’s loan forgiveness amount to the lender. If a borrower did not apply for loan forgiveness, payments were to be deferred 10 months after the end of the covered period for the borrower’s loan forgiveness (between 8 and 24 weeks). Some or all of the loan could be forgiven if at least 75 % of the loan proceeds were used by the Company to cover payroll costs, including benefits, and if the Company maintained its employment and compensation within certain parameters during the period following the loan origination date and complied with other relevant conditions. The Company elected to account for the PPP loan as an in-substance government grant by applying the guidance in International Accounting Standards 20 by analogy based on the assessment that it is probable that it will meet both (a) the eligibility criteria for a PPP loan, and (b) the loan forgiveness criteria for all or substantially all of the PPP loan. Under this guidance, the Company recorded the loan proceeds in other income in the condensed consolidated statement of operations for the three and nine months ended September 30, 2021. Note 13 — Subsequent Events On October 13, 2022, the Company’s PPP Loan dated May 5, 2021 was forgiven for the full amount of $ 190,100 (see Note 12). 15 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2022, and related notes included elsewhere in this filing. This discussion and analysis and other parts of this filing contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this filing. You should carefully read the “Risk Factors” section of this filing to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Cautionary Note Regarding Forward-Looking Statements” in this filing. Overview This overview and outlook provide a high-level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this report. About SeqLL We are a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields. We leverage our expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute major advancements to scientific research and development. Our customers are primarily the early adopters of genomics technology and tSMS in academic research, biomarker discovery, and molecular diagnostic product development. Since our incorporation in 2014, we have devoted the majority of our efforts to technology development, business planning, and advancing research collaborations. We incurred net losses of $925,949 and $639,499 for the three months ended September 30, 2022 and 2021, respectively, and net losses of $2,858,818 and $2,306,420 for the nine months ended September 30, 2022 and 2021 respectively. We had negative cash flow from operating activities of $2,913,571 and $1,022,971 for the nine months ended September 30, 2022 and 2021, respectively, and had an accumulated deficit of $17,272,669 as of September 30, 2022. Results of operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond our control. Our business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business. Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our consolidated financial statements and the notes thereto within the Consolidated Financial Statements section of this report, and trends discussed in “Risk Factors” in Item 1-A of Part II of this report. 16 Results of Operations Comparison of the Three Months Ended September 30, 2022 and 2021 The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021: Three months ended September 30, 2022 2021 Revenue Sales $ - $ 15,937 Grant revenue - 34,964 Total revenue - 50,901 Cost of sales - 4,049 Gross profit - 46,852 Operating expenses Research and development 428,771 90,658 General and administrative 489,729 360,944 Total operating expenses 918,500 451,602 Operating loss (918,500 ) (404,750 ) Other (income) and expenses Unrealized loss on marketable securities 242 - Interest income (9,981 ) - Other income - (93 ) Change in fair value of convertible notes - 193,776 Interest expense 17,188 41,066 Net loss $ (925,949 ) $ (639,499 ) Net loss per share - basic and diluted $ (0.08 ) $ (0.09 ) Weighted average common shares - basic and diluted 11,886,379 7,171,232 Revenues Our revenues during the three months ended September 30, 2022 were $0 as compared to revenues of $50,901 during the three-month period ended September 30, 2021, representing a decrease of $50,901, or 100%. During the three months ended September 30, 2022, no revenue generating activities were performed, nor were any grants provided to us compared to revenue in the same period of 2021 with $15,937 of product sales and grants of $34,964. The decrease in revenue was due to the reduction in research services and business activities due to our relocation to Billerica, Massachusetts. This relocation, which was finalized in September 2022, resulted in our temporarily not having facilities that were sufficient to perform our research services and business activities. We expect to resume normal operations in the final quarter of 2022. In addition, there was no grant revenue during the three months ended September 30, 2022 due primarily to 2022 being the final year of the award. Gross Profit Gross profit for the three months ended September 30, 2022 was $0, as compared to gross profit of $46,852 for the three months ended September 30, 2021, due to the fact that we had no revenue in the three month period ended September 30, 2022. Research and Development Expenses Research and development expenses increased by $338,113, or 373%, from $90,658 for the three months ended September 30, 2021 to $428,771 for the three months ended September 30, 2022. The increase in expenses was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. We expect these expenditures to increase over the final quarter of 2022 and beyond as we increase our research and development efforts to pre-pandemic levels. 17 General and Administrative Expenses General and administrative expenses increased by $128,785 or 36%, from $360,944 for the three months ended September 30, 2021 compared to $489,729 for the three months ended September 30, 2022. The increase was primarily attributable to increased operating expenses as a public company, including the addition of accounting, legal and audit related expenses as well as increased payroll expense of approximately $130,000. General and administrative expenditures will continue to increase during 2022 to support ongoing financial reporting and compliance activities. Interest and Other Income/Loss We recognized $9,981 of interest income in the three-month period ended September 30, 2022. No such income was noted for the three-month period ended September 30, 2021. We recognized $193,776 related to the change in fair value of our convertible notes in the three-month period ended September 30, 2021. No such convertible notes were in existence for the three-month period ended September 30, 2022. We recognized interest expense of $17,188 and $41,066 in the three months ended September 30, 2022 and 2021, respectively, representing a decrease of $23,878, or 58%. The decrease in interest expense was due to a decrease in our outstanding indebtedness as a result of the conversion of $2.1 million in notes to equity concurrently with the consummation of our initial public offering on August 31, 2021. Net Loss Overall, the net loss increased by $286,450, or 45%, to $925,949 as compared to $639,499 for the three months ended September 30, 2021. The increase in net loss was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic and our increase in general and administrative expenses that are related to being a public company. Comparison of the Nine Months Ended September 30, 2022 and 2021 The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021: Nine months ended September 30, 2022 2021 Revenue Sales $ 1,177 $ 48,021 Grant revenue 77,482 127,009 Total revenue 78,659 175,030 Cost of sales 690 44,792 Gross profit 77,969 130,238 Operating expenses Research and development 1,129,286 133,074 General and administrative 1,700,340 1,173,565 Total operating expenses 2,829,626 1,306,639 Operating loss (2,751,657 ) (1,176,401 ) Other (income) and expenses Unrealized loss (gain) on marketable securities (54,266 ) - Realized loss on marketable securities 106,324 - Interest income (18,457 ) - Other income - (190,193 ) Change in fair value of convertible notes - 195,962 Loss on extinguishment of convertible notes - 934,257 Interest expense 73,560 189,993 Net loss $ (2,858,818 ) $ (2,306,420 ) Net loss per share - basic and diluted $ (0.24 ) $ (0.41 ) Weighted average common shares - basic and diluted 11,886,379 5,642,100 18 Revenues Our revenues during the nine months ended September 30, 2022, were $78,659 as compared to revenues of $175,030 during the nine months ended September 30, 2021, representing a decrease of $96,371, or 55%. During the nine months ended September 30, 2022, revenue included grants of $77,482 and $1,777 of revenues from product sales, and no sales from research services as compared to revenue in the same period of 2021 from product sales of $31,537, grants of $127,009 and $16,484 in research services. The decrease in revenue was due to the reduction in research services and revenue generating activities due to our relocation to Billerica, Massachusetts. This relocation, which was finalized in September of 2022, resulted in our temporarily not having facilities that were sufficient to perform our research services and business activities. We expect to resume normal operations in the final quarter of 2022 Gross Profit Gross profit for the nine months ended September 30, 2022 was $77,969, as compared to gross profit of $130,238 for the nine months ended September 30, 2021, which represented a decrease of $52,269, or 40%, primarily due to the fact that we had immaterial product and research services sales in 2022 due to our relocation to Billerica, Massachusetts as well as decreased grant revenue for the nine month period ended September 30, 2022. Research and Development Expenses Research and development expenses increased by $996,212, or 749%, from $133,074 for the nine months ended September 30, 2021 compared to $1,129,286 for the nine months ended September 30, 2022. The increase in expenses was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. We expect these expenditures to increase in the last quarter of 2022 and beyond as we increase our research and development efforts to pre-pandemic levels. General and Administrative Expenses General and administrative expenses increased by $526,775, or 45%, from $1,173,565 for the nine months ended September 30, 2021 compared to $1,700,340 for the nine months ended September 30, 2022. The increase was primarily attributable to increased operating expenses as a public company, including the addition of accounting, legal and audit related expenses as well as increased payroll expense of approximately $530,000. General and administrative expenditures will continue to increase during the remainder of 2022 to support ongoing financial reporting and compliance activities. Interest and Other Income/Loss We recognized $52,058 in net realized and unrealized losses on the marketable securities during the nine months ended September 30, 2022. We did not hold such investments during the nine months ended September 30, 2021. We recognized $18,457 of interest income in the nine-month period ended September 30, 2022. No such income was noted for the nine-month period ended September 30, 2021. In the nine-month period ended September 30, 2021, we recognized $190,193 from the receipt of funds in connection with the PPP pursuant to the CARES Act that was signed into law on March 27, 2020. No such receipt was noted for the nine-month period ended September 30, 2022. We recognized $195,962 related to the change in fair value of our convertible notes in the nine months ended September 30, 2021. No such convertible notes were in existence for the nine months ended September 30, 2022. We recognized a loss on extinguishment of debt totaling $934,257 in the nine-month period ended September 30, 2021 related to certain convertible notes. The loss on the extinguishment of debt represented the excess of the fair value of these convertible notes totaling $3,075,987 over their carrying value of $2,141,730 at their amendment date in the first quarter of 2021. We did not incur such losses during the nine months ended September 30, 2022. We recognized interest expense of $73,560 and $189,993 in the nine months ended September 30, 2022 and 2021, respectively, representing a decrease of $116,433, or 61%. The decrease in interest expense was due to a decrease in our outstanding indebtedness as a result of the conversion of $2.1 million in notes to equity concurrently with the consummation of our initial public offering on August 31, 2021. 19 Net Loss Overall, the net loss increased by $552,398, or 24%, to $2,858,818 as compared to $2,306,420 for the nine months ended September 30, 2021. This increase in net loss is primarily attributable to increased operating expenses as a public company and our progressive return to research and development activities to levels of pre-COVID-19 pandemic. This increase in operating expenses was offset by our loss on extinguishment of our convertible notes in the nine months ended September 30, 2021 in the amount of $934,257. No such loss occurred during the nine-month period ended September 30, 2022. Liquidity and Capital Resources The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Even though we experienced negative cash flows from operations of $2,913,571 for the nine months ended September 30, 2022, as a result of our recent common stock offering in August 2021, we had cash and cash equivalents of $4,453,521 and short-term investments in marketable securities of $2,499,685 at September 30, 2022. As of September 30, 2022, we had $4,453,521 of cash and cash equivalents. Cash and cash equivalents increased $438,393 at September 30, 2022 as compared to December 31, 2021 due to the sale of approximately $5.9 million in our marketable securities, offset by the purchase of approximately $2.5 million of marketable securities, and cash spending for operating activities for the nine-month period ended September 30, 2022. Since inception, we have funded our operations primarily through equity and debt financings, as well as from modest sales of products and research services. As of September 30, 2022, we had an accumulated deficit of $17,272,669. In August 2021, we issued 3,060,000 shares of common stock to investors in our initial public offering. The gross proceeds from our initial public offering was $13.0 million. We incurred offering expenses of $1.6 million in cash. We also converted $2.1 million of debt into 641,895 shares of common stock at our initial public offering. On September 29, 2021, we issued 189,000 shares of common stock to the underwriters at a price of $4.24 per share from the partial exercise of the overallotment option, increasing the net proceeds by approximately $730,000, net of offering costs. We believe the net proceeds from our initial public offering, together with our cash generated from commercial sales and research activity, will enable us to fund our operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Our future capital requirements will depend on many factors, including: ● our ability to successfully further develop our technologies and create innovative products in our markets, including the costs associated with the development of our tSMS platform across multiple market segments, for which we have budgeted approximately $1 million in 2022 and $2 million in 2023 in support of our collaborative efforts in detection tools for heart disease and cancer, and chromatin mapping in genome biology; ● scientific progress in research and development of our collaborative programs, including the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights, as well as the costs associated with any product or technology that we may in-license or acquire; and ● the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; including the need to enter into other collaborations to enhance or complement our product and service offerings. We plan to continue seeking additional financing sources from time to time to meet our working capital requirements, make continued investment in research and development and make capital expenditures needed for us to maintain and expand our business. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited. In addition, if we raise additional funds through further issuances of equity or debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. 20 Cash Flows The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented. Nine Months Ended September 30, 2022 2021 Cash proceeds (used in) provided by: Operating activities $ (2,913,571 ) $ (1,022,971 ) Investing activities 3,351,964 (5,250 ) Financing activities - 12,334,906 Net increase in cash and cash equivalents $ 438,393 $ 11,306,685 Net cash used in operating activities Net cash used in operating activities was approximately $2.9 million and $1.0 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in operating spending was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. In addition, we experienced an increase in our general and administrative spending since we became a public company in August 2021. We anticipate our research and development efforts and on-going general and administrative costs will generate negative cash flows from operating activities for the foreseeable future. Net cash used in investing activities Net cash provided by (used in) investing activities was approximately $3.3 million and immaterial for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily attributable to our sales of our entire portfolio of marketable securities during the first quarter of 2022, which is offset by our purchases of additional marketable securities in the third quarter of 2022. Net cash provided by financing activities Net cash provided by financing activities was $0 and approximately $12.3 million for the nine months ended September 30, 2022 and 2021, respectively. This increase is attributable to our initial public offering that occurred in August of 2021 and the related issuance of common stock, settlement of convertible notes, and payment of offering related expenses. 21 Recent Accounting Pronouncements In August 2020, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We adopted this standard on January 1, 2022, which had no material impact to our condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”) which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to our condensed consolidated financial statements. We do not believe that any other recently issued but not yet effective accounting pronouncements are expected to have a material effect on our consolidated financial statements. Critical Accounting Policies and Estimates We prepare our financial statements and accompanying notes in conformity with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions about future events that affect reported amounts. Estimations are considered critical accounting estimates based on, among other things, its impact on the portrayal of our financial condition, results of operations, or liquidity, as well as the degree of difficulty, subjectivity, and complexity in its deployment. Critical accounting estimates address accounting matters that are inherently uncertain due to unknown future resolution of such matters. Management routinely discusses the development, selection, and disclosure of each critical accounting estimates. Other than those noted within Note 2 to our unaudited consolidated financial statements, there have been no significant changes to our critical accounting policies and estimates during the three-and nine-month periods ended September 30, 2022 as compared to the information contained in our 2021 Form 10-K filed with the SEC. Reference should be made to the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 for a full description of other significant accounting policies. 22 JOBS Act Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. For as long as we remain an emerging growth company under the recently-enacted JOBS Act, we will, among other things: ● be permitted to have only two years of audited financial statements and only two years of related selected financial data and management’s discussion and analysis of financial condition and results of operations disclosure; ● be entitled to rely on an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; ● be entitled to reduced disclosure obligations about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and ● be exempt from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements. We currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an “emerging growth company.” Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our common stock may be materially and adversely affected. Item 3. Quantitative and Qualitative Disclosures about Market Risk Not required under Regulation S-K for smaller reporting companies. Item 4. Controls and Procedures. Evaluation of disclosure controls and procedures Our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) as of September 30, 2022. As of September 30, 2022, based upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective. Disclosure controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Changes in Internal Control Over Financial Reporting There was no change in our internal control over financial reporting that occurred during the nine months ended September 30, 2022 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls Our disclosure controls and procedures and internal control over financial reporting are designed to reasonably ensure that designed control objectives are achieved. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. 23 PART II - OTHER INFORMATION Item 1. Legal Proceedings None Item 1A. Risk Factors There have been no material changes to the risk factors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 23, 2022 ( our “Annual Report”) or our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 filed with the SEC on May 12, 2022 and August 12, 2022, respectively (collectively, our “Quarterly Reports”). Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Annual Report and our Quarterly Reports, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as included in our Annual Report. The risks and uncertainties described in our Annual Report, our Quarterly Reports and this report are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment. Item 2. Unregistered Securities Sales of Equity Securities and Use of Proceeds Sales of Unregistered Securities There have been no sales of unregistered securities within the period covered by this report that would be required to be disclosed pursuant to Item 701 of Regulation S-K. Repurchases of Shares or of Company Equity Securities None. Item 3. Default Upon Senior Securities None Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information None. 24 Item 6. Exhibits The following documents are filed as a part of this report or incorporated herein by reference: Exhibit Number Description 31.1 Certification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certifications of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certifications of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 25 SIGNATURES Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SEQLL INC. Date: November 8, 2022 /s/ Daniel Jones Daniel Jones Chief Executive Officer (Principal Executive Officer) Date: November 8, 2022 /s/ Frances Scally Frances Scally Chief Financial Officer (Principal Financial and Accounting Officer) 26